All-trans Retinoic Acid Promotes Nerve Cell Differentiation of Yolk Sac-Derived Mesenchymal Stem Cells

2014 ◽  
Vol 174 (2) ◽  
pp. 682-692 ◽  
Author(s):  
Yuhua Gao ◽  
Chunyu Bai ◽  
Kunfu Wang ◽  
Bo Sun ◽  
Weijun Guan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Retinoic Acid ◽  
Cell Differentiation ◽  
Nerve Cell ◽  
Yolk Sac ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Nerve Cell Differentiation

scholarly journals The effect of all‐trans retinoic acid (ATRA) and mesenchymal stem cells (MSCs) transplantation on increased expression of Foxp3 and IL‐10

2008 ◽  
Vol 22 (S1) ◽  
Author(s):  
Sun‐Young Ju ◽  
Kyung‐Ah Cho ◽  
Yun‐Jae Jung ◽  
Su‐Jin Cho ◽  
Kyung‐Ha Ryu ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Retinoic Acid ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

scholarly journals All-Trans Retinoic Acid Improves the Effects of Bone Marrow-Derived Mesenchymal Stem Cells on the Treatment of Ankylosing Spondylitis: AnIn VitroStudy

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Deng Li ◽  
Peng Wang ◽  
Yuxi Li ◽  
Zhongyu Xie ◽  
Le Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Retinoic Acid ◽  
Ankylosing Spondylitis ◽  
Protective Factor ◽  
Interleukin 17 ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Treg Subset

Previous studies have demonstrated the immunosuppressive effects of both all-trans retinoic acid (ATRA) and mesenchymal stem cells (MSCs). The present study aimed to assess the immunoregulatory effects of ATRA on MSCs in the treatment of ankylosing spondylitis (AS). Bone marrow-derived MSCs from healthy donors were pretreated with ATRA and cocultured with CD3/28-activated peripheral blood mononuclear cells (PBMCs) derived from AS patients. Frequencies of Th17 and regulatory T (Treg) cells were analyzed using flow cytometry. The secretion and the mRNA level of key cytokines were measured with cytometric bead array and quantitative real-time PCR, respectively. ATRA pretreatment increased interleukin-6 (IL-6) secretion of MSCs. Th17 and Treg subset populations were increased and reduced by ATRA-pretreated MSCs, respectively. ATRA-pretreated MSCs significantly decreased not only the vital pathogenic cytokine in AS, tumor necrosis factor-α(TNF-α), but also AS-boosting factors interleukin-17 (IL-17A) and interferon-γ(IFN-γ). These results indicated that IL-6 may be a potential protective factor in AS and highlighted the promising role of ATRA in improving the efficacy of MSC-based treatment of AS.

Sign in / Sign up

Export Citation Format

Share Document